British Biotech: Difference between revisions
m accessyear {{cite web}} parameter cleanup using AWB |
m deprecated parameters cleanup using Project:AWB |
||
| Line 39: | Line 39: | ||
| work = IPO Summary Report |
| work = IPO Summary Report |
||
| publisher = NEA |
| publisher = NEA |
||
| accessdate = 1 December |
| accessdate = 1 December 1992 |
||
| accessyear = 1992 |
|||
}}</ref> |
}}</ref> |
||
| Line 64: | Line 63: | ||
| work = Journal of Clinical Oncology |
| work = Journal of Clinical Oncology |
||
| publisher = American Society of Clinical Oncology |
| publisher = American Society of Clinical Oncology |
||
| accessdate = 16 June |
| accessdate = 16 June 1998 |
||
| accessyear = 1998 |
|||
}}</ref>) and zacutex (for [[pancreatitis]]). |
}}</ref>) and zacutex (for [[pancreatitis]]). |
||
| Line 78: | Line 76: | ||
| work = Select Committee on Science and Technology |
| work = Select Committee on Science and Technology |
||
| publisher = House of Commons |
| publisher = House of Commons |
||
| accessdate = 13 August |
| accessdate = 13 August 1998 |
||
| accessyear = 1998 |
|||
}}</ref> These events were the subject of an inquiry by the House of Commons Select Committee on Science and Technology in August 1998 which absolved Dr Millar of any responsibility for the company’s problems.<ref name="report" /> Subsequent investigations by the [[Securities and Exchange Commission]], [[Food and Drug Administration]], [[London Stock Exchange]] and the European Medicines Evaluation Agency found that British Biotech had willfully misled the public about the progress of marimastat <ref name="sec">{{cite web |
}}</ref> These events were the subject of an inquiry by the House of Commons Select Committee on Science and Technology in August 1998 which absolved Dr Millar of any responsibility for the company’s problems.<ref name="report" /> Subsequent investigations by the [[Securities and Exchange Commission]], [[Food and Drug Administration]], [[London Stock Exchange]] and the European Medicines Evaluation Agency found that British Biotech had willfully misled the public about the progress of marimastat <ref name="sec">{{cite web |
||
| last = |
| last = |
||
| Line 90: | Line 87: | ||
| work = Nature Biotechnology |
| work = Nature Biotechnology |
||
| publisher = Nature Publishing Group |
| publisher = Nature Publishing Group |
||
| accessdate = 18 July |
| accessdate = 18 July 1999 |
||
| accessyear = 1999 |
|||
}}</ref> and that unblinding data before the end of clinical trials does not necessarily invalidate the results.<ref name="ipupdate">{{cite web |
}}</ref> and that unblinding data before the end of clinical trials does not necessarily invalidate the results.<ref name="ipupdate">{{cite web |
||
| last = |
| last = |
||
| Line 102: | Line 98: | ||
| work = IP/IT Update |
| work = IP/IT Update |
||
| publisher = NIPC |
| publisher = NIPC |
||
| accessdate = 15 February |
| accessdate = 15 February 1999 |
||
| accessyear = 1999 |
|||
}}</ref> Marimastat underwent Phase III trials in collaboration with [[Schering-Plough|Schering-Plough Corporation]].<ref name="marupdate">{{cite web |
}}</ref> Marimastat underwent Phase III trials in collaboration with [[Schering-Plough|Schering-Plough Corporation]].<ref name="marupdate">{{cite web |
||
| last = |
| last = |
||
| Line 125: | Line 120: | ||
| work = Select Committee on Science and Technology |
| work = Select Committee on Science and Technology |
||
| publisher = House of Commons |
| publisher = House of Commons |
||
| accessdate = 14 September |
| accessdate = 14 September 1998 |
||
| accessyear = 1998 |
|||
}}</ref> The corporate politics behind the downfall of British Biotech was later recorded for a [[BBC2]] Series "Blood on The Carpet".<ref name="bloodcarpet">{{cite web |
}}</ref> The corporate politics behind the downfall of British Biotech was later recorded for a [[BBC2]] Series "Blood on The Carpet".<ref name="bloodcarpet">{{cite web |
||
| last = |
| last = |
||
| Line 137: | Line 131: | ||
| work = |
| work = |
||
| publisher = BBC |
| publisher = BBC |
||
| accessdate = |
| accessdate =2001 |
||
| accessyear = 2001 |
|||
}}</ref> |
}}</ref> |
||
Revision as of 11:26, 3 December 2009
| Industry | Biotechnology |
|---|---|
| Founded | 1986 |
| Defunct | 2003 |
| Fate | Merged |
| Successor | company merged into Vernalis |
| Headquarters | Oxford, United Kingdom |
Key people | CEO Keith McCullagh, 1986-1998 Elliot Goldstein, 1998-2002 Tim Edwards, 2002-2003 Chair Brian Richards, 1986-1998 Christopher Hampson, 1998-2002 Peter Fellner, 2002-2003 |
Number of employees | 500 |
British Biotech was a British based biotech company.
British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards,[1] and was the first British biotechnology company to be publicly listed when it was floated on 1 July 1992 [2]
In 1996, despite having no compounds on or near the market, it was temporarily valued at nearly $2.5 billion [3], largely on the basis of its two main development drugs, marimastat (a novel matrix metalloprotease inhibitor for cancer treatment [4]) and zacutex (for pancreatitis).
In February 1998, Dr Andrew Millar was dismissed as Head of Clinical Research and went on to make allegations that "the Board were running a business plan consistent only with extreme and unfounded optimism" .[5] These events were the subject of an inquiry by the House of Commons Select Committee on Science and Technology in August 1998 which absolved Dr Millar of any responsibility for the company’s problems.[5] Subsequent investigations by the Securities and Exchange Commission, Food and Drug Administration, London Stock Exchange and the European Medicines Evaluation Agency found that British Biotech had willfully misled the public about the progress of marimastat [6] and that unblinding data before the end of clinical trials does not necessarily invalidate the results.[7] Marimastat underwent Phase III trials in collaboration with Schering-Plough Corporation.[8] Further development of zacutex was abandoned due to poor clinical trial results.[9] The corporate politics behind the downfall of British Biotech was later recorded for a BBC2 Series "Blood on The Carpet".[10]
In 2003, British Biotech merged with RiboTargets and then into Vernalis. The British Biotech company name disappeared after this merger and remaining staff integrated into the Vernalis organisation in Winnersh, Berkshire.
External links
References
- ^ "The Final Death Knell of Chicago's G.D. Searle". Midwest Business. 2003. Retrieved 12 May 2003.
{{cite web}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ "BBIOY IPO". IPO Summary Report. NEA. 1992. Retrieved 1 December 1992.
{{cite web}}: Check date values in:|accessdate=(help); Cite has empty unknown parameter:|coauthors=(help) - ^ "Ten years of biotech gaffes". Nature Biotechnology. Nature Publishing Group. 2006. Retrieved 8 March 2006.
{{cite web}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ "Phase I trial of Marimastat". Journal of Clinical Oncology. American Society of Clinical Oncology. 1998. Retrieved 16 June 1998.
{{cite web}}: Check date values in:|accessdate=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ a b "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 13 August 1998.
{{cite web}}: Check date values in:|accessdate=(help); Cite has empty unknown parameter:|coauthors=(help) - ^ "Nature Biotechnology". Nature Biotechnology. Nature Publishing Group. 1999. Retrieved 18 July 1999.
{{cite web}}: Check date values in:|accessdate=(help); Cite has empty unknown parameter:|coauthors=(help) - ^ "Shedding Biotech's Bad Name". IP/IT Update. NIPC. 1999. Retrieved 15 February 1999.
{{cite web}}: Check date values in:|accessdate=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ "Marimastat Update". BusinessWire. 2001. Retrieved 2 May 2001.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help) - ^ "Zacutex UK Phase III clinical data presented at American Gastroenterological Association". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 14 September 1998.
{{cite web}}: Check date values in:|accessdate=(help); Cite has empty unknown parameter:|coauthors=(help) - ^ "BBC2's Blood on the Carpet". BBC. 2001. Retrieved 2001.
{{cite web}}: Check date values in:|accessdate=(help); Cite has empty unknown parameter:|coauthors=(help)